Immuneering
IMRX
38 hedge funds and large institutions have $316M invested in Immuneering in 2021 Q3 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
46.67% more ownership
Funds ownership: 0% → 46.67% (+47%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$83.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$60.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$55.2M |
| 4 |
BlackRock
New York
|
+$41M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$29.3M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIM
26
MetLife Investment Management
Whippany,
New Jersey
| $98.7K | +$99.9K | +3,719 | New |
|
27
JP Morgan Chase
New York
| $84K | +$85.1K | +3,167 | New |
|
|
MLICM
28
Metropolitan Life Insurance Company (MetLife)
New York
| $74.7K | +$75.6K | +2,814 | New |
|
|
SO
29
STRS Ohio
Columbus,
Ohio
| $50K | +$51.1K | +1,900 | New |
|
30
New York State Common Retirement Fund
Albany,
New York
| $45K | +$45.7K | +1,700 | New |
|
31
Citigroup
New York
| $33K | +$33.5K | +1,246 | New |
|
32
UBS Group
Zurich,
Switzerland
| $30K | +$30.1K | +1,119 | New |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| $23K | +$23.4K | +872 | New |
|
34
Legal & General Group
London,
United Kingdom
| $20K | +$20.8K | +774 | New |
|
|
AIP
35
Ameritas Investment Partners
Lincoln,
Nebraska
| $17K | +$17K | +634 | New |
|
36
Bank of America
Charlotte,
North Carolina
| $14K | +$14.6K | +542 | New |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| $6K | +$6.26K | +233 | New |
|
38
Wells Fargo
San Francisco,
California
| $1K | +$1.18K | +44 | New |
|
IMRX Hedge Fund Activity: Q3 2021 in Review
38 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q3 2021, worth a combined $316M.
Buyers outnumbered sellers: 38 funds opened new IMRX positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $83.7M.
- 38 institutional investors held Immuneering (IMRX) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $316M of Immuneering stock for Q3 2021.
- 38 funds opened new Immuneering positions in Q3 2021 and 0 closed out, a net change of +38 holders.
- The largest Immuneering buyer in Q3 2021 was T. Rowe Price Associates, an estimated $83.7M added.
Based on aggregated 13F filings for Q3 2021.